Published in Mol Cell on October 08, 2015
Advances in the molecular genetics of gliomas - implications for classification and therapy. Nat Rev Clin Oncol (2016) 0.96
Targeting bet bromodomain proteins in solid tumors. Oncotarget (2016) 0.89
Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System Tumors. Cureus (2016) 0.85
Systematic characterization of lncRNAs' cell-to-cell expression heterogeneity in glioblastoma cells. Oncotarget (2016) 0.78
GBM heterogeneity as a function of variable epidermal growth factor receptor variant III activity. Oncotarget (2016) 0.77
Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery. J Cancer Res Clin Oncol (2016) 0.76
Prospective Isolation and Comparison of Human Germinal Matrix and Glioblastoma EGFR(+) Populations with Stem Cell Properties. Stem Cell Reports (2017) 0.75
Homeobox genes gain trimethylation of histone H3 lysine 4 in glioblastoma tissue. Biosci Rep (2016) 0.75
Old player, new partner: EGFRvIII and cytokine receptor signaling in glioblastoma. Nat Neurosci (2016) 0.75
Small genomic insertions form enhancers that misregulate oncogenes. Nat Commun (2017) 0.75
Integrating RNA sequencing into neuro-oncology practice. Transl Res (2017) 0.75
Multiplexed RNAi therapy against brain tumor-initiating cells via lipopolymeric nanoparticle infusion delays glioblastoma progression. Proc Natl Acad Sci U S A (2017) 0.75
Elevated FOXG1 and SOX2 in glioblastoma enforces neural stem cell identity through transcriptional control of cell cycle and epigenetic regulators. Genes Dev (2017) 0.75
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Hallmarks of cancer: the next generation. Cell (2011) 140.01
edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics (2009) 67.17
Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet (2007) 32.41
Cancer genome landscapes. Science (2013) 25.33
Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell (2010) 23.97
Selective inhibition of BET bromodomains. Nature (2010) 18.79
Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc Natl Acad Sci U S A (2010) 15.13
Mutational landscape and significance across 12 major cancer types. Nature (2013) 14.91
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
A unique chromatin signature uncovers early developmental enhancers in humans. Nature (2010) 14.02
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Discovery and saturation analysis of cancer genes across 21 tumour types. Nature (2014) 11.68
A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer (2011) 11.33
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol (2011) 9.60
Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell (2013) 8.37
Transcriptional amplification in tumor cells with elevated c-Myc. Cell (2012) 8.24
c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell (2012) 6.49
Emerging landscape of oncogenic signatures across human cancers. Nat Genet (2013) 6.48
Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell (2004) 6.35
Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science (2013) 6.29
Exploring the genomes of cancer cells: progress and promise. Science (2011) 6.16
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science (2014) 6.09
Transforming fusions of FGFR and TACC genes in human glioblastoma. Science (2012) 5.09
Slug and Sox9 cooperatively determine the mammary stem cell state. Cell (2012) 4.77
Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell (2014) 4.04
The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem (1997) 4.03
Epigenetic reprogramming in cancer. Science (2013) 3.47
Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res (2006) 3.31
Interplay between the cancer genome and epigenome. Cell (2013) 3.05
Transcriptional regulation and its misregulation in disease. Cell (2013) 2.92
Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science (2014) 2.91
Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther (2007) 2.89
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov (2012) 2.61
The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol Cell (2014) 2.47
Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. Cancer Cell (2012) 2.45
Mapping human epigenomes. Cell (2013) 2.44
Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol (2013) 2.24
Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat Rev Cancer (2014) 2.10
Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science (2013) 2.00
mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metab (2013) 1.86
The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J Clin Invest (2013) 1.76
Establishing intracranial brain tumor xenografts with subsequent analysis of tumor growth and response to therapy using bioluminescence imaging. J Vis Exp (2010) 1.39
An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma. Cell Rep (2013) 1.35
EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. Cell Metab (2013) 1.23
Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nat Rev Cancer (2015) 1.15
Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling. Science (2014) 1.13
De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov (2013) 1.07
Oncogenic role of SOX9 expression in human malignant glioma. Med Oncol (2012) 0.99
MiR-145 functions as a tumor-suppressive RNA by targeting Sox9 and adducin 3 in human glioma cells. Neuro Oncol (2013) 0.99
Transcription factors FOXG1 and Groucho/TLE promote glioblastoma growth. Nat Commun (2013) 0.88
Integrative analysis of haplotype-resolved epigenomes across human tissues. Nature (2015) 1.40
Isoform Switch of TET1 Regulates DNA Demethylation and Mouse Development. Mol Cell (2016) 0.77